Back to Newsroom

PolarityTE™ Lead Product, SkinTE™, is Approved for Use by Multiple Medical Institutions

SALT LAKE CITY, Oct. 19, 2017 (GLOBE NEWSWIRE) — PolarityTE, Inc. (NASDAQ:COOL) today announced that multiple value analysis committees have approved SkinTE™ for use at their respective medical institutions as the Company continues its commercialization efforts and manufacturing scale-up.  Clinical application is expected in the fourth quarter of 2017, and data is planned to be released through multiple channels in the first half of 2018.